Persistent Interleukin‐18 Fuels Expansion of CD38 + HLA ‐ DR + CD8 + T Cells in Still Disease and Macrophage Activation Syndrome
Arthritis & Rheumatology · 15.09.2026
DOI: 10.1002/art.70319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 15.09.2026. Verfasst von Greta Rogani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Rheumatology and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, University of Utrecht, Utrech…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dutch Arthritis Association.
Abstract (Originalsprache)
Objective
Still disease (SD) is an autoinflammatory disorder characterized by remarkably high interleukin‐18 (IL‐18) levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further IL‐18 elevation and expansion of CD38 + HLA‐DR + CD8 + T cells. However, whether and when this population emerges during SD remains unknown. We therefore examined CD38 + HLA‐DR + CD8 + T cells across disease stages.
Methods
CD38 + HLA‐DR + CD8 + T cells were analyzed longitudinally: at SD onset (therapy‐naive; n = 19), during clinically inactive disease (n = 15), and before or at MAS occurrence (n = 12). Spectral flow cytometry and bulk RNA sequencing were performed. Correlations with clinical and laboratory parameters were assessed. In vitro cytokine stimulations of healthy donor (HD)–derived peripheral blood mononuclear cells and CD8 + lymphocytes were performed to explore mechanisms driving differentiation of these cells.
Results
CD38 + HLA‐DR + CD8 + T cells were expanded from SD onset and peaked in MAS (median: 4.61% and 31.7%, respectively, versus 0.87% in HDs). Transcriptomic profiling of these cells revealed enrichment of activation, cytotoxicity, and proliferation programs, which were confirmed at the protein level. Frequencies correlated with markers of systemic inflammation, T cell activation, and serum IL‐18 levels. Sustained IL‐18 stimulation in vitro induced robust and persistent expansion of CD38 + HLA‐DR + CD8 + cells, recapitulating key ex vivo phenotypic features.
Conclusion
CD38 + HLA‐DR + CD8 + cells, previously primarily associated with MAS, are detectable early in SD. Persistent IL‐18 exposure promotes their expansion. These findings identify CD38 + HLA‐DR + CD8 + T cells as a potential mechanistic link between SD and MAS and highlight this subset as a candidate therapeutic target. image
Autor:innen und Institutionen
- Department of Pediatric Rheumatology and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
- Center for Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
- Multiplex Core Facility, Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Pediatric Immuno-Rheumatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Flow Cytometry Service, Clinical Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
ORCID-Profile: Greta Rogani, Remco G A Erkens, Alejandra Bodelón, Freya M C H Huijsmans, Francesca S Minoia
Förderung
- Dutch Arthritis Association
Zitieren
APA
Rogani, G., Erkens, R. G. A., Bodelón, A., Mocking, T. R., Putmans, M. T. M., Huijsmans, F. M. C. H., Sijbers, L. J. P. M., De Ligt, A. M., Van Haaren, M. J. H., Scholman, R. C., Dautzenberg, N. M. M., Meesters-Ensing, J. I., Rossano, M., Porretti, L., Nierkens, S., Minoia, F. S., Vastert, S. J., & van Loosdregt, J. (2026). Persistent Interleukin‐18 Fuels Expansion of CD38 + HLA ‐ DR + CD8 + T Cells in Still Disease and Macrophage Activation Syndrome. Arthritis & Rheumatology. https://doi.org/10.1002/art.70319
Vancouver
Rogani G, Erkens RGA, Bodelón A, Mocking TR, Putmans MTM, Huijsmans FMCH, et al. Persistent Interleukin‐18 Fuels Expansion of CD38 + HLA ‐ DR + CD8 + T Cells in Still Disease and Macrophage Activation Syndrome. Arthritis & Rheumatology. 2026. doi:10.1002/art.70319
BibTeX
@article{Rogani2026,
author = {Rogani, Greta and Erkens, Remco G A and Bodelón, Alejandra and Mocking, Tim R and Putmans, Marein T M and Huijsmans, Freya M C H and Sijbers, Lyanne J P M and De Ligt, Aafke M and Van Haaren, Maurice J H and Scholman, Rianne C and Dautzenberg, Noël M M and Meesters-Ensing, Joyce I and Rossano, Martina and Porretti, Laura and Nierkens, Stefan and Minoia, Francesca S and Vastert, Sebastiaan J and van Loosdregt, Jorg},
title = {Persistent Interleukin‐18 Fuels Expansion of CD38 + HLA ‐ DR + CD8 + T Cells in Still Disease and Macrophage Activation Syndrome},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70319}
}
EUVIMED